• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai, July 30 Lupin Ltd has acquired Germany’s Hormosan Pharma GmbH, a sales and marketing generics company that specialises in supplying Central Nervous System (CNS) medicines, at an undisclosed sum.

Hormosan clocked sales of €6.8 million for the year ended December 2007 and its acquisition marks Lupin’s long awaited deal in Europe, besides an entry into Germany.

The German company develops licenses and markets a range of generics in Germany, and has complementary products in the cardiovascular segment, as well, Lupin said.

Germany’s pharmaceutical market is estimated to be about $45 billion, with $14 billion of this being the generic drugs market.

Dr Desh Bandhu Gupta, Chairman, said that the German acquisition was in line with its strategy to tap into the potential of other leading global pharma markets.

The company still has an appetite for acquisitions, he said and added that Japan was now on its radar.

Lupin shares were up over two per cent on the BSE, at Rs 734 on Wednesday.

More Stories on : Mergers & Acquisitions | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
ABB bags Rs 455-cr Vedanta order

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line